172 related articles for article (PubMed ID: 21609324)
1. Metabolic effects and cost-effectiveness of aripiprazole versus olanzapine in schizophrenia and bipolar disorder.
Kasteng F; Eriksson J; Sennfält K; Lindgren P
Acta Psychiatr Scand; 2011 Sep; 124(3):214-25. PubMed ID: 21609324
[TBL] [Abstract][Full Text] [Related]
2. Cost-effectiveness of atypical antipsychotics for the management of schizophrenia in the UK .
Davies A; Vardeva K; Loze JY; L'italien GJ; Sennfalt K; Baardewijk Mv
Curr Med Res Opin; 2008 Nov; 24(11):3275-85. PubMed ID: 18947458
[TBL] [Abstract][Full Text] [Related]
3. Cost-effectiveness of olanzapine vs. aripiprazole in the treatment of schizophrenia.
Ascher-Svanum H; Stensland MD; Peng X; Faries DE; Stauffer VL; Osuntokun OO; Kane JM
Curr Med Res Opin; 2011 Jan; 27(1):115-22. PubMed ID: 21110749
[TBL] [Abstract][Full Text] [Related]
4. Cost-effectiveness Analysis of Aripiprazole Once-Monthly for the Treatment of Schizophrenia in the UK.
Tempest M; Sapin C; Beillat M; Robinson P; Treur M
J Ment Health Policy Econ; 2015 Dec; 18(4):185-200. PubMed ID: 26729007
[TBL] [Abstract][Full Text] [Related]
5. UK cost-consequence analysis of aripiprazole in schizophrenia: diabetes and coronary heart disease risk projections (STAR study).
Barnett AH; Millar HL; Loze JY; L'Italien GJ; van Baardewijk M; Knapp M
Eur Arch Psychiatry Clin Neurosci; 2009 Jun; 259(4):239-47. PubMed ID: 19267255
[TBL] [Abstract][Full Text] [Related]
6. Healthcare costs associated with treatment of bipolar disorder using a mood stabilizer plus adjunctive aripiprazole, quetiapine, risperidone, olanzapine or ziprasidone.
Jing Y; Kim E; You M; Pikalov A; Tran QV
J Med Econ; 2009 Jun; 12(2):104-13. PubMed ID: 19527195
[TBL] [Abstract][Full Text] [Related]
7. Cost-effectiveness of lurasidone vs aripiprazole among patients with schizophrenia who have previously failed on an atypical antipsychotic: an indirect comparison of outcomes from clinical trial data.
Rajagopalan K; Hassan M; O'Day K; Meyer K; Grossman F
J Med Econ; 2013 Jul; 16(7):951-61. PubMed ID: 23701260
[TBL] [Abstract][Full Text] [Related]
8. Intramuscular aripiprazole in the control of agitation.
Currier GW; Citrome LL; Zimbroff DL; Oren D; Manos G; McQuade R; Pikalov AA; Crandall DT
J Psychiatr Pract; 2007 May; 13(3):159-69. PubMed ID: 17522559
[TBL] [Abstract][Full Text] [Related]
9. Cost-effectiveness of olanzapine in the first-line treatment of schizophrenia in China.
Zhao J; Jiang K; Li Q; Zhang Y; Cheng Y; Lin Z; Xuan J
J Med Econ; 2019 May; 22(5):439-446. PubMed ID: 30732487
[TBL] [Abstract][Full Text] [Related]
10. Evaluation of akathisia in patients with schizophrenia, schizoaffective disorder, or bipolar I disorder: a post hoc analysis of pooled data from short- and long-term aripiprazole trials.
Kane JM; Barnes TR; Correll CU; Sachs G; Buckley P; Eudicone J; McQuade R; Tran QV; Pikalov A; Assunção-Talbott S
J Psychopharmacol; 2010 Jul; 24(7):1019-29. PubMed ID: 20008446
[TBL] [Abstract][Full Text] [Related]
11. Cost-effectiveness of long-acting injectable aripiprazole once-monthly 400 mg in bipolar I disorder in the USA.
Augusto M; Greene M; Touya M; Sweeney SM; Waters H
J Comp Eff Res; 2018 Jul; 7(7):637-650. PubMed ID: 29694244
[TBL] [Abstract][Full Text] [Related]
12. Aripiprazole for the maintenance treatment of bipolar I disorder: A review.
McIntyre RS
Clin Ther; 2010; 32 Suppl 1():S32-8. PubMed ID: 20152551
[TBL] [Abstract][Full Text] [Related]
13. Aripirazole-olanzapine combination for treatment of schizophrenia.
Duggal HS
Can J Psychiatry; 2004 Feb; 49(2):151. PubMed ID: 15065751
[No Abstract] [Full Text] [Related]
14. Cost effectiveness of paliperidone palmitate versus risperidone long-acting injectable and olanzapine pamoate for the treatment of patients with schizophrenia in Sweden.
Mehnert A; Nicholl D; Pudas H; Martin M; McGuire A
J Med Econ; 2012; 15(5):844-61. PubMed ID: 22458756
[TBL] [Abstract][Full Text] [Related]
15. A comparison of weight change during treatment with olanzapine or aripiprazole: results from a randomized, double-blind study.
McQuade RD; Stock E; Marcus R; Jody D; Gharbia NA; Vanveggel S; Archibald D; Carson WH
J Clin Psychiatry; 2004; 65 Suppl 18():47-56. PubMed ID: 15600384
[TBL] [Abstract][Full Text] [Related]
16. Predictive value of early changes in triglycerides and weight for longer-term changes in metabolic measures during olanzapine, ziprasidone or aripiprazole treatment for schizophrenia and schizoaffective disorder post hoc analyses of 3 randomized, controlled clinical trials.
Hoffmann VP; Case M; Stauffer VL; Jacobson JG; Conley RR
J Clin Psychopharmacol; 2010 Dec; 30(6):656-60. PubMed ID: 21105275
[TBL] [Abstract][Full Text] [Related]
17. Comparison of metabolic syndrome incidence among schizophrenia patients treated with aripiprazole versus olanzapine or placebo.
L'Italien GJ; Casey DE; Kan HJ; Carson WH; Marcus RN
J Clin Psychiatry; 2007 Oct; 68(10):1510-6. PubMed ID: 17960964
[TBL] [Abstract][Full Text] [Related]
18. Cost analysis of the adverse reactions of bipolar disorder treatment with aripiprazole and olanzapine in Spain.
Rubio-Terrés C; Rubio-Rodríguez D; Baca-Baldomero E
Actas Esp Psiquiatr; 2014; 42(5):242-9. PubMed ID: 25179096
[TBL] [Abstract][Full Text] [Related]
19. Cost-effectiveness of adjunctive therapy with atypical antipsychotics for acute treatment of major depressive disorder.
Taneja C; Papakostas GI; Jing Y; Baker RA; Forbes RA; Oster G
Ann Pharmacother; 2012 May; 46(5):642-9. PubMed ID: 22550279
[TBL] [Abstract][Full Text] [Related]
20. A pharmacoeconomic analysis of sertindole in the treatment of schizophrenia in Sweden.
Lindström E; Eberhard J; Fors BM; Hansen K; Sapin C
Nord J Psychiatry; 2011 Dec; 65(6):403-13. PubMed ID: 21770821
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
